Finding a way for the ‘right’ microbiome to help cancer immunotherapy work

Could tweaking the microbiome optimize the way immunotherapy works in cancer patients?

A recent study from MD Anderson Cancer Center found that a microbiome padded with specific “good bacteria” could improve the efficacy of certain immunotherapies.

MD Anderson is building on that finding, collaborating with the Parker Institute for Cancer Immunotherapy and Cambridge, Mass., biotech Seres Therapeutics to develop a cancer-targeting bacterial cocktail. The idea is to develop a microbiome-altering drug that helps buoy the body’s immune response, helping immunotherapy take effect.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In